Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Item | Description | The company |
---|---|---|
EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Gilead Sciences Inc. EBITDA increased from 2022 to 2023 but then decreased significantly from 2023 to 2024. |
Enterprise Value to EBITDA Ratio, Current
Selected Financial Data (US$ in millions) | |
Enterprise value (EV) | 155,978) |
Earnings before interest, tax, depreciation and amortization (EBITDA) | 4,434) |
Valuation Ratio | |
EV/EBITDA | 35.18 |
Benchmarks | |
EV/EBITDA, Competitors1 | |
AbbVie Inc. | 28.43 |
Amgen Inc. | 15.90 |
Bristol-Myers Squibb Co. | 50.44 |
Danaher Corp. | 22.07 |
Eli Lilly & Co. | 52.94 |
Johnson & Johnson | 15.58 |
Merck & Co. Inc. | 9.42 |
Pfizer Inc. | 10.16 |
Regeneron Pharmaceuticals Inc. | 11.67 |
Thermo Fisher Scientific Inc. | 18.29 |
Vertex Pharmaceuticals Inc. | 242.97 |
EV/EBITDA, Sector | |
Pharmaceuticals, Biotechnology & Life Sciences | 21.64 |
EV/EBITDA, Industry | |
Health Care | 19.93 |
Based on: 10-K (reporting date: 2024-12-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Enterprise value (EV)1 | 158,992) | 109,266) | 122,947) | 97,096) | 102,914) | |
Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 4,434) | 10,496) | 8,852) | 11,329) | 4,133) | |
Valuation Ratio | ||||||
EV/EBITDA3 | 35.86 | 10.41 | 13.89 | 8.57 | 24.90 | |
Benchmarks | ||||||
EV/EBITDA, Competitors4 | ||||||
AbbVie Inc. | 26.97 | 20.79 | 13.31 | 13.44 | 21.34 | |
Amgen Inc. | 15.31 | 14.13 | 12.97 | 13.22 | 12.24 | |
Bristol-Myers Squibb Co. | 48.23 | 6.51 | 9.46 | 8.65 | 34.35 | |
Danaher Corp. | 22.34 | 26.41 | 18.42 | 21.05 | 26.68 | |
Eli Lilly & Co. | 55.98 | 85.33 | 37.74 | 29.85 | 23.67 | |
Johnson & Johnson | 15.77 | 16.45 | 14.78 | 14.47 | 18.20 | |
Merck & Co. Inc. | 9.90 | 51.30 | 13.91 | 12.18 | 16.05 | |
Pfizer Inc. | 10.60 | 22.50 | 6.12 | 8.64 | 15.78 | |
Regeneron Pharmaceuticals Inc. | 13.55 | 20.16 | 15.27 | 6.68 | 12.70 | |
Thermo Fisher Scientific Inc. | 19.89 | 21.83 | 20.25 | 20.21 | 18.72 | |
Vertex Pharmaceuticals Inc. | 231.93 | 21.57 | 14.91 | 18.92 | 14.81 | |
EV/EBITDA, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | 22.07 | 22.59 | 13.58 | 13.16 | 18.90 | |
EV/EBITDA, Industry | ||||||
Health Care | 19.95 | 18.98 | 13.71 | 13.87 | 16.50 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
3 2024 Calculation
EV/EBITDA = EV ÷ EBITDA
= 158,992 ÷ 4,434 = 35.86
4 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | Gilead Sciences Inc. EV/EBITDA ratio decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level. |